Regeneron buys 23andMe Getty ImagesRegeneron Pharmaceuticals announced on Monday it will acquire bankrupt genomics firm 23andMe for $256 million through a bankruptcy auction, promising to maintain ethical standards in handling sensitive customer DNA information.According to Reuters, the New York-based pharmaceutical giant aims to leverage 23andMe’s extensive database of over 15 million customer DNA samples to enhance its genomic-driven drug discovery processes. The acquisition comes at a crucial time as con ...

Core Viewpoint - Regeneron Pharmaceuticals is acquiring 23andMe out of bankruptcy for $256 million, gaining access to a significant collection of genetic data and samples from over 15 million customers, which raises privacy concerns [1][4]. Company Acquisition Details - The acquisition includes 23andMe's Personal Genome Service, Total Health and Research Services, and its biobank [1]. - The deal is expected to close in the third quarter of 2025, pending bankruptcy court and regulatory approvals [2]. Privacy and Compliance - Regeneron has committed to adhering to 23andMe's consumer-privacy rules and will collaborate with a court-appointed ombudsman to ensure compliance [3]. - The company aims to protect the dataset with high standards of data privacy and security [3]. Background on 23andMe - 23andMe was once valued at over $6 billion after going public in 2021 but has since dropped to a valuation of approximately $50 million due to various issues, including a $30 million settlement related to a data breach affecting nearly 7 million users [4][5]. - The company filed for bankruptcy in March, prompting the California Attorney General to advise customers to delete their data from 23andMe's database [5][8]. Leadership Changes - Anne Wojcicki, co-founder and CEO of 23andMe, stepped down on the day of the bankruptcy filing following internal conflicts with the board [9]. - All seven independent board members of 23andMe resigned in September, indicating significant governance issues within the company [9].

Core Insights - The House Committee on Energy and Commerce is investigating 23andMe's Chapter 11 bankruptcy filing and is concerned about the potential compromise of sensitive genetic data [1] - Several congressmen have requested information from 23andMe regarding its data and privacy practices, highlighting ongoing concerns about the company's data security commitments [2][4] - 23andMe, which gained popularity with its at-home DNA testing kits, has faced challenges in generating recurring revenue and establishing a profitable research and therapeutics business, leading to its bankruptcy filing [3] Company Overview - 23andMe was once valued at a peak of $6 billion but has struggled financially, resulting in its assets, including a vast genetic database, being put up for sale following its bankruptcy filing in March [3] - The company has not yet responded to inquiries regarding its data security practices, raising further concerns among lawmakers [4]

Core Viewpoint - 23andMe has filed for Chapter 11 bankruptcy, raising concerns about the potential sale of its extensive genetic data, which could be valuable to various entities, including biomedical startups and law enforcement [6][3][4]. Company Overview - 23andMe has sold over 12 million at-home DNA testing kits since its inception in 2006, assisting users in finding ancestors and assessing health risks [5]. - The company was once valued at $6 billion but is now undergoing bankruptcy proceedings [6]. Data Privacy Concerns - There is a significant risk that 23andMe's genetic data could be sold to the highest bidder, which raises privacy concerns for customers [2][3]. - The company asserts that the bankruptcy filing will not change how it manages customer data and that any potential buyer must comply with applicable laws regarding data treatment [9]. - A consumer privacy ombudsman may be appointed if personally identifiable information is sold during the bankruptcy process, ensuring alignment with the company's privacy policy [10][12]. Regulatory Environment - There is currently no federal genetic privacy law in the U.S., although some states, like California, have consumer protections in place [13]. - The inadequacy of 23andMe's data deletion procedures has been highlighted, as the company retains certain information even after account deletion [14]. Cybersecurity Issues - 23andMe has faced data breaches in the past, contributing to its current financial troubles [15]. - The sensitivity of genetic data is emphasized, as it not only pertains to individuals but also to their family members [15]. Customer Actions and Recommendations - Customers are advised to contact 23andMe to request data deletion, although the effectiveness of this action is uncertain [16]. - There is a call for more robust regulations regarding the handling of sensitive genetic data in the long term [16].